TLRY Tilray

Tilray Brands Launches XMG Zero, a New ‘Better for You’ Cannabis Beverage

Tilray Brands Launches XMG Zero, a New ‘Better for You’ Cannabis Beverage

XMG Cannabis Brand Releases Latest Innovations with XMG Zero and XMG+ Beverages Now Available Across Canada

TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced a bold new range of cannabis-infused beverages from , under two of its sub-brands: XMG Zero and XMG Plus (“XMG+”). XMG Zero, an extension of XMG’s original core line, now offers two new THC beverages: Cream Soda Zero and Orange Soda Zero. XMG+, a boosted version of XMG original, focuses on high CBG and guarana extract (for naturally occurring caffeine), while revealing their new Banana Brain Freeze and Iced Rocket Berry flavours. Recognized for their diverse offerings and unique profiles including a variety of THC and CBG ratios, XMG is reshaping the cannabis beverage market with unparalleled variety and quality. 

XMG has been the #1 brand in cannabis-infused beverages with the largest product line available in Canada1, serving as a top trusted brand in the cannabis beverage space with go-to options consumers know and love.

XMG’S latest innovations from XMG Zero include:

  • Cream Soda Zero: A dreamy blend of vanilla and caramel flavours with 0 sugar and 0 calories in a 355 mL can featuring 10mg of THC.
  • Orange Soda Zero: Enjoy a nostalgic burst of bold orange soda with 0 sugar and 0 calories in a 355 mL format can featuring 10mg of THC.
  • Black Cherry Zero: This refreshing beverage is the same formulation of XMG’s Black Cherry Alt, featuring the same fruity blend of black cherry sweetness in a 355mL can featuring 10mg of THC.
  • Cherry Cola (Coming soon): An elevated nostalgic beverage that’s as classic as it sounds.

XMG’s latest innovations from its XMG+ line, include: 

  • XMG+ Banana Brain-Freeze: Peel away your worries with this banana-flavoured bonanza featuring 10mg THC and 10mg CBG, including guarana extract in a 355mL can.
  • XMG+ Iced Rocket Berry: Ignite your tastebuds with an ice-cold blast of berry and lime featuring 10mg THC and 10mg CBG, including guarana extract in a 355mL can.

XMG continues to dominate the ready-to-drink cannabis beverage space with its new releases from XMG Zero and XMG+, providing consumers with a variety of flavours and cannabinoid options to explore all summer long.

To find XMG’s most recent thirst quenchers, and to keep up with the latest news from XMG, follow on social. 



About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with four distinct and complementary business segments including medical and adult-use cannabis, medical distribution, wellness foods, and beverage-alcohol. Tilray Brands is on a mission to change people’s lives for the better – one person at a time - by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis and consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, today Tilray Brands’ unprecedented and diversified production platform supports a portfolio of best-in-class brands in over 20 countries including comprehensive adult-use and medical cannabis offerings, hemp-based foods, and craft beverages across North America, Europe, Australia, and Latin America. 

For more information on Tilray Brands, visit . and follow @Tilray on Instagram, Twitter, Facebook, and LinkedIn. 



Forward-Looking Statements
 

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. 

Contacts: 

Media: 

Kaitlin Macapagal 

Investors 

Raphael Gross 

203-682-8253 

 

1 Source: Hifyre Data, National Beverage Sales, March 2024

 



EN
02/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tilray

 PRESS RELEASE

Tilray Brands and the Carlsberg Group Enter into an Exclusive Multi-Ye...

Tilray Brands and the Carlsberg Group Enter into an Exclusive Multi-Year U.S. Brewing and Commercial Partnership NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), a leading global consumer packaged goods company and the fourth-largest craft beer brewer in the United States, today announced that it has entered into an exclusive licensing agreement starting January 1, 2027 with the Carlsberg Group, one of the world’s premier brewing organizations and among the largest globally by revenue. Under the terms of the agreement, Tilray has been granted a m...

 PRESS RELEASE

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich...

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich durch eine strategische Vereinbarung mit Smartway Pharmaceuticals CC-Pharma-Vereinbarung fördert das Wachstum von Tilray im Vereinigten Königreich und stärkt den Vertrieb über Apotheken- und Krankenhauskanäle NEW YORK und LONDON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass ihr europäisches pharmazeutisches Vertriebsunternehmen CC Pharma eine strategische Vereinbarung mit , einem führenden pharmazeutischen Vertriebspartner...

 PRESS RELEASE

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni g...

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la division pharmaceutique de Tilray Brands, Inc. (Nasdaq : TLRY ; TSX : TLRY), a annoncé aujourd'hui que son activité de distribution pharmaceutique européenne, CC Pharma, a conclu un accord stratégique avec , un partenaire de distribution pharmaceutique...

 PRESS RELEASE

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement wi...

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals CC Pharma Agreement Bolsters Tilray’s UK Growth, Strengthening Distribution to Pharmacy and Hospital Channels NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with , a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products...

 PRESS RELEASE

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in De...

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in Deutschland ausgezeichnet Die Auszeichnung würdigt CC Pharma als innovativen Marktführer und vertrauenswürdigen Partner auf dem europäischen Pharmamarkt DENSBORN, Deutschland, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass , ihr europäischer Pharmahändler, zu einem der ernannt wurde. Hierbei handelt es sich um eine der renommiertesten und unabhängigsten Auszeichnungen für Innovation bei kleinen und mittleren Unternehmen des La...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch